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Abstract
Dopaminergic neurons in the substantia nigra pars compacta (SNpc) are characterized by
the expression of genes required for dopamine synthesis, handling and reuptake and the ex-
pression of these genes is largely controlled by nuclear receptor related 1 (Nurr1). Nurr1 is
also expressed in astrocytes and microglia where it functions to mitigate the release of
proinflammatory cytokines and neurotoxic factors. Given that Parkinson’s disease (PD) path-
ogenesis has been linked to both loss of Nurr1 expression in the SNpc and inflammation, in-
creasing levels of Nurr1 maybe a promising therapeutic strategy. In this study a novel Nurr1
agonist, SA00025, was tested for both its efficiency to induce the transcription of dopaminer-
gic target genes in vivo and prevent dopaminergic neuron degeneration in an inflammation
exacerbated 6-OHDA-lesion model of PD. SA00025 (30mg/kg p.o.) entered the brain and
modulated the expression of the dopaminergic phenotype genes TH, VMAT, DAT, AADC
and the GDNF receptor gene c-Ret in the SN of naive rats. Daily gavage treatment with
SA00025 (30mg/kg) for 32 days also induced partial neuroprotection of dopaminergic neu-
rons and fibers in rats administered a priming injection of polyinosinic-polycytidylic acid (poly
(I:C) and subsequent injection of 6-OHDA. The neuroprotective effects of SA00025 in this
dopamine neuron degeneration model were associated with changes in microglial morpholo-
gy indicative of a resting state and a decrease in microglial specific IBA-1 staining intensity in
the SNpc. Astrocyte specific GFAP staining intensity and IL-6 levels were also reduced. We
conclude that Nurr1 agonist treatment causes neuroprotective and anti-inflammatory effects
in an inflammation exacerbated 6-OHDA lesion model of PD.
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Introduction
Dopaminergic neurons in the substantia nigra pars compacta (SNpc) are characterized by the
expression of specific genes required for dopamine regulation and the expression of these
genes is controlled by the nuclear receptor related 1 (Nurr1) protein [1,2,3]. Abolishing
Nurr1 causes the loss of this essential dopaminergic phenotype in vitro [4] and in vivo [5].
Specifically, Nurr1 is required for the transcription of tyrosine hydroxylase (TH), vesicular
monoamine transporter (VMAT), dopamine active transporter (DAT) and aromatic l-amino
acid decarboxylase (AADC) and hence plays a fundamental role in both the differentiation of
dopaminergic neurons in embryonic stages and the long-term maintenance of the dopami-
nergic phenotype throughout life [1,2,3]. Polymorphisms in the NURR1 gene have been iden-
tified in patients with both sporadic and familial forms of Parkinson’s disease (PD) [6,7,8,9],
however the prevalence of these mutations is rare. Although the role of wild-type Nurr1 in
the onset and progression of PD is not well established, there is a reduced expression in the
SNpc with increased age [10], which is the major risk factor in the development of PD. Re-
duced Nurr1 expression is also observed in PD patients compared to age matched controls
[11,12]. Nurr1 (+/-) knock out mice and tamoxifen inducible Nurr1 (-/-) knock out mice dis-
play a dopamine neuronal phenotype [13], a reduction of dopamine release [13] and show
progressive behavioral deficits [14], whereas embryonic Nurr1 (-/-) knock out mice die by
post natal day two [15]. Conversely, overexpressing Nurr1 using a viral vector rescues a-
synuclein mediated degeneration of dopaminergic neurons by restoring GDNF levels [16].
Nurr1 also causes the induction of brain-derived neurotrophic factor (BDNF) transcription
[17]. Therefore neurotrophic factors may also act synergistically to promote dopaminergic
neuron survival.
In addition, Nurr1 negatively regulates inflammation [18], which is also considered a risk
factor for the development of PD [19]. We have previously shown that toll-like receptor 4
(TLR4) stimulation by lipopolysaccharide (LPS) or activation of TLR3 by polyinosinic-
polycytidylic acid (poly(I:C)) primes dopaminergic neurons for a subsequent oxidative stress
insult, caused by 6-hydroxydopamine (6-OHDA) [20,21]. This results in exacerbated midbrain
dopamine neuron degeneration compared to 6-OHDA given alone [20,21]. Administration of
an interleukin-1 receptor antagonist in this model resulted in significant reductions of the pro-
inflammatory cytokines TNFα and IFNγ and attenuated the loss of dopamine neurons [21].
We have previously found that a low dose of 6-OHDA does not cause major midbrain dopa-
mine degeneration without prior inflammatory stimulant priming [20, 21]. A single low dose
injection of poly(I:C) or LPS induces the expression of inflammatory markers at 7–12 days
post injection in the SNpc, which then subsides [20, 21]. In a proof of concept study, at that
time-point retrograde degeneration of the vulnerable dopamine neurons (caused by low-dose
intrastriatal 6-OHDA-degeneration) was almost doubled by this prior TLR-induced cytokine
peak in the substantia nigra [21]. Following inflammatory stimulation on TLRs, Nurr1 acts as a
transcription factor for the removal of NF-kB from the promoter regions of proinflammatory
cytokine genes, which would otherwise cause their transcription [18]. The suppression of dam-
aging reactive oxygen species signals from astrocytes and microglia is also negatively regulated
by Nurr1 levels [18]. Nurr1 knock down in microglia and astrocytes of mice exacerbates dopa-
minergic neuron degeneration in the SN caused by an LPS injection [18].
Therefore given Nurr1’s role in both dopaminergic neuronal phenotype maintenance and
in mitigating pro-inflammatory signals, increasing Nurr1 levels or activating Nurr1 may be a
promising strategy for the treatment of PD [22]. In the following we describe the neuroprotec-
tive and anti-inflammatory effect of a novel Nurr1 agonist compound in an inflammation exac-
erbated 6-OHDA lesion model of PD.
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Materials and Methods
Animals
Female Sprague-Dawley rats weighing ~250 g (Charles River Laboratories) were housed in
standard conditions with ad libitum access to food and water under a 12/12 hour light/dark
cycle. This work was approved by the McLean Hospital IACUC under protocol 13-6/2-14.
Nurr1 agonist treatment paradigms
The Nurr1 agonist (SA00025) (reference: A.G. Almario, P. Lardennois, A. Olivier, PCT Int.
Appl. (2008), WO2008034974A1) was received from Sanofi. On each day testing a 30mg/kg
working solution of SA00025 was made fresh by dissolving SA00025 in 0.6% methylcellulose
and 0.5% Tween-80 in distilled water. 0.6% methylcellulose and 0.5% Tween-80 in distilled
water was used as the vehicle. In the first experimental paradigm naive rats were gavaged daily
for 7 consecutive days. In this paradigm rats were killed at 1, 4, 12 or 24 hrs after the last gavage
(N = 3–4/group). In the second experimental paradigm, treatment was started 1 day post intra-
nigral poly I:C injection (day 1) and was administered daily for the duration of the experiment
(32 days), including during the day rats received intra-striatal 6-OHDA (day 12). Rats were
sacrificed 24 hrs after the final administration of SA00025 (day 33), (N = 8/group).
PK analysis
Rats were terminally anesthetized and perfused transcardially with heparinized saline (0.1%
heparin in 0.9% saline) and whole brains were removed and weighed. Brains were homoge-
nized in distilled water at a volume (μl) that was 2x brain weight. A 5μL aliquot of sample was
injected onto a Phenomenex Luna C8 (50x2.0 mm) 5 mmHPLC column with a Shimadzu
SILHTC auto sampler and an integrated HPLC pumping system Shimadzu LC10AD. The
compound was detected by an Sciex API 5000 Mass Spectrometer with a positive ESI ionization
mode. Mobile phase A was 95% acetonitrile in water, mobile phase B was 10 mM ammonium
acetate buffer in water, pH 7.0 with a flow rate of 500 μL/min. The starting condition for HPLC
gradient was 25:75 (A/B) at time 0 min, 100:0 (A/B) from 0.1 to 1.9 min and 25:75 (A/B) from
2 to 3 min. Multiple reaction monitoring (MRM) was used to monitor the compound with m/z
transitions 363.2–347.2 and a retention time of 1.25 min.
qPCR
For gene expression analysis, the RNA was extracted from dissected SN tissue samples using
RNeasy Mini spin kit and shredder columns (Qiagen, USA) according to manufacturers in-
structions. 85–150 ng of RNA was used for cDNA preparation using Superscript III First-
Strand Synthesis System (Invitrogen) according to manufacturers instructions. Quantitative
qPCR was performed with SYBER Green Master Mix and qPCR primers (Taqman premade
and validated primers for TH, VMAT, DAT, c-RET and Nurr1). The expression of the gene of
interest was determined in triplicate samples for the cDNA preparation made for each rat SN
sample. The Ct value of each target gene was normalized against the Ct value of the reference
gene (Ct(target)-Ct(GAPDH)). Results were analyzed using the ΔΔCt method (ΔCt(Nurr1 ago-
nist treated)-ΔCt(vehicle treated control)). The relative expression caused by the Nurr1 agonist
compound was calculated by 2^-ΔΔCt and represented as fold change compared to compared
to vehicle treatment (= 1).
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Western Blot analysis
Rats were terminally anesthetized and perfused transcardially with heparinized saline (0.1%
heparin in 0.9% saline) and brains were cut in serial sections to 1mm. The SN was dissected
from each rat and each suspended in ice cold buffer containing: 300 mM sucrose in TE buffer
(Bio-Rad). Phosphatase inhibitors I and II (1:100), proteinase inhibitors (1:100) (Thermo Halt
proteinase inhibitor single use cocktail) and EDTA (Thermo) (1:100) were then added. Tissues
were homogenized for 15 secs and sonicated with three 1 second pulses. 30mg protein homoge-
nates, determined by a BSA assay (Pierce), were loaded on to each gel, using the Criterion pre-
cast 4–12.5% SDS polyacrylamide gel system (Bio-Rad). The proteins were then transferred to
a PVDF membrane at 21 V and 2.5 amps. Membranes were washed in Tris-buffered saline
with 0.1% Tween 20 (TBS-T) and then blocked in 5% protein blocker (Bio-Rad). The mem-
brane was then incubated overnight at 4°C in anti-TH (Pel-Freez 1:1000) and anti-GAPDH
(Millipore, 1:5000). HRP-conjugated secondary antibodies were applied to the membranes for
1 h at room temperature. The blot was treated with ECL-Plus (Amersham Biosciences) and ex-
posed using ChemiDoc XRS and image Lab software to visualize the bands. Optical density
analysis (NIH image) was used to determine the relative abundance of TH compared to
GAPDH levels.
Stereotaxic delivery of polyI:C and 6-OHDA
Stereotaxic surgery and polyI:C/ 6-OHDA solution preparation was performed according to
[20]. In brief, rats were first anesthetized with ketamine and xylazine (60 mg/kg and 3 mg/kg
respectively, i.p.). A total of 20 μg of poly(I:C) (Axxora), in a volume of 2μl, was then delivered
to the SN by stereotaxic injection at a rate of 0.5 μl/min using microinfusion pumps (Stoelting
Co, Wood Dale, IL) with a 5 minute wait time after injection. The stereotaxic coordinates used
for the intra-nigral injection of poly(I:C) were: AP:− 5.5 mm, ML: − 2.0 mm, and DV: 7.5 mm
relative to bregma. Following surgery rats were returned to home cages for 11 days before
being re-anesthetized for intra-striatal 6-OHDA delivery. Rats were injected with 5μg of
6-OHDA (Sigma-Aldrich, St Louis, MO), prepared as free base, in a single 3.5 μl deposit at a
rate of 0.5 μl/ min. A 5 min wait time was allowed after injection. Striatal injection coordinates
were as follows: AP: +0.2, ML: − 3.0, DV: − 5.0 relative to bregma.
Histology
Rats were terminally anaesthetized with sodium pentobarbital and perfused transcardially with
25 ml of heparinised saline (0.1%) followed by 100 ml of 4% paraformaldehyde in phosphate
buffer. Brains were post-fixed in 4% paraformaldehyde for 24 h before placing them in 30% su-
crose. Coronal sections were cut to 40 μm, and stored in antifreeze at -20°C until use. For
immunohistochemistry, sections were washed in PBS followed by 3% hydrogen peroxide for 7
min to quench endogenous peroxidases. After three washes in PBS, the sections were incubated
in 5% normal goat serum in 0.1% Triton X-100 in PBS for 1 hour before the following primary
antibodies were added: Anti-IBA1 (Wako, 1:200), anti-NeuN (Millipore, 1:1000) or anti-TH
(Pel-Freez 1:500). Primary antibodies were left at 4°C overnight. After washing in PBS, sections
were incubated in goat anti-mouse/ rabbit biotinylated secondary antibody (Vector Laborato-
ries 1:200). Staining of the tissue-bound antibody was visualized using a standard peroxidase-
based method using an ABC kit (Vector Laboratories) and chromogen, 3,30-diaminobenzadine
(DAB, Sigma). NeuN and TH co-stains were done sequentially and nicklel added to the DAB
reaction for anti-NeuN peroxidase reaction. Following immunohistochemistry tissue sections
were mounted onto slides, dehydrated and coverslipped.
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For co-immunofluorescence stains, tissue sections were incubated in blocking solution with
anti-IBA1 (Wako, 1:200) and anti-GFAP (Chemicon, 1:1000) at 4°C and left overnight. Sec-
tions were washed in 3x in PBS and incubated with Alexa Fluor secondary antibodies (Life
Technologies, 1:200) in PBS and applied for 2 hrs at room temperature. Sections were washed
in 3x in PBS and mounted on slides. Coverslips were added using aqueous mounting media.
Multiplex ELISA
Tissue samples were collected and suspended in PBS, with the addition of phosphatase inhibi-
tors I-II (1:100) and protease inhibitors (1:100), (Thermo Halt proteinase inhibitor single use
cocktail). Samples were homogenized and a portion of the supernatant was reserved for protein
determination (BCA Assay, Pierce). Samples were then analyzed for the simultaneous detec-
tion of IL10, IL6, IL1a, MCP1, MIP1a, MIP2, MIP3a, RANTES, TNFa, Fractalkine, ILb, IL-2,
MDC and TGFb1 using a multiplex ELISA based format for rat protein detection, performed
in triplicate. Testing was performed independently through Aushon BioSystems using the Cira
immunoassay platform and the relative amounts of proteins determined for Nurr1 agonist and
vehicle treated rat tissue in pg/mg.
Histological quantification and statistics
Estimates of the number of remaining dopamine neurons in the SNpc were quantified on sec-
tions using Stereo Investigator (MBF Bioscience), by an investigator bind to the treatment con-
ditions. Dopamine neurons that were TH and NeuN positive were quantified, on both the
contralateral and ipsilateral sides, using the Optical Fractionater Workflow function at the fol-
lowing defined parameters: number of sections (4–5/ rat), section evaluation interval 6 and the
measured section thickness (~18–25μm/ section) at 20x magnification. Guard zones were set
to 4μm. Counts were presented as a% of the contralateral side.
Results
SA00025 entered the brain and modulated the transcription of
dopaminergic target genes
The structure of the small molecule Nurr1 agonist used in this study is shown in Fig. 1A.
SA00025 is a potent agonist of Nurr1 (EC50 2.5nM) in HEK293 cells transfected with full
length human Nurr1. The agonist was not found to activate panel of 40 other nuclear receptors,
including RXR (manuscript in preparation). SA00025 was given by daily oral administration of
30mg/kg for 7 days (Fig. 1B). Following 7 days of daily oral treatment, PK analysis or post mor-
tem showed that SA00025 entered the brain and confirmed elevated brain exposure at 1, 4 and
24 hrs after the last administration (F3,18 = 31.22, p<0.001). The compound was present in
brain homogenates at 1-hour after the final oral treatment and reached a maximum concentra-
tion at 4 hours (Fig. 1C). SA00025 treatment significantly modulated the expression of Nurr1
and dopaminergic target genes from 1–48 hrs after oral administration for 7 days (F3,18 = 5.61,
p<0.05). Specifically, SA00025 induced a transcriptional upregulation of Nurr1, TH and
VMAT at 1-hour post daily oral treatment and a transcriptional downregulation of VMAT,
DAT and c-RET at 4 hours post Nurr1 agonist treatment (Fig. 1D). A normalization of Nurr1,
TH and VMAT mRNA expression was observed at 4 hours post oral administration and an in-
crease in c-Ret observed at 24 hrs (Fig. 1D). Concomitantly, protein levels of TH were signifi-
cantly elevated at 4 hours following Nurr1 agonist treatment (F3,18 = 3.22, p<0.05) compared
to vehicle treatment (Fig. 1E).
Nurr1 Agonist Treatment in a Parkinson's Disease Rat Model
PLOS ONE | DOI:10.1371/journal.pone.0121072 March 27, 2015 5 / 14
Fig 1. SA00025 entered the brain andmodulated the transcription of dopaminergic target genes. The chemical structure of SA00025: 2-{3-[2-
(4-chlorophenyl)imidazo[1,2-a]-pyridin-6-yl]phenyl}propan-2-ol (A). The Nurr1 agonist compound was administered once daily for 7 consecutive days (30mg/
kg/ day) in naive rats by oral gavage (B). The compound was observed in the brain at 1 hour after the last gavage and reached a maximum concentration at 4
hrs post-gavage treatment (C). High levels of the compound were still observed in the brains of rats at 24 hrs and returned to baseline at 48 hrs (C). SA00025
caused a transcriptional upregulation of Nurr1, TH and VMAT at 1-hour post daily gavage and a transcriptional downregulation of VMAT, DAT and c-RET at 4
hours post-gavage treatment (D). A normalization of Nurr1, TH and VMAT expression was observed at 4–48 hours post-gavage treatment (D). Transcription
of all dopaminergic target genes was equivalent between compound and vehicle treated rats at 48 hours post-gavage treatment (D). TH protein levels were
elevated at 4 hours post-gavage treatment (E). Significance is annotated as p<0.05* & p<0.001*** compared vehicle treatment (dashed lines), unpaired
T-tests and ANOVA. N = 4–8/ group. Graphs are expressed as mean ± SEM.
doi:10.1371/journal.pone.0121072.g001
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SA00025 caused neuroprotection in the 6-OHDA lesion model primed
with the TLR3 dsRNA inflammatory stimulant (poly(I:C))
The neuroprotective and anti-inflammatory effect of SA00025 was tested in a model of viral-
like inflammation exacerbated by oxidative damage from 6-OHDA [20]. In this model [20]
rats first receive an initial unilateral injection of poly(I:C) in the SN (Start—day 0) and then
after 12 days a second unilateral infusion of low dose 6-OHDA in the dopamine terminal re-
gion of the striatum (Fig. 2A). Rats were also administered the Nurr1 agonist or vehicle
throughout the paradigm period (day 1–32) and were sacrificed at day 33 (Fig. 2A). Appropri-
ate brain exposure of the compound was confirmed in this experiment with elevated brain lev-
els measured 24h after treatment (T1,16 = 9.81, p<0.001), (Fig 2B). Our post-mortem analysis
showed that the Nurr1 agonist compound was neuroprotective on TH and NeuN positive neu-
rons within the SNpc, using unbiased stereology, and also preserved TH positive fibers in the
striatum, as observed by densitometry measurements (Fig. 2C). Rats had a significant sparing
of dopaminergic neurons in the SNpc after 32 days of treatment with the Nurr1 agonist com-
pound (T1,16 = 2.16, p<0.05), compared to vehicle conditions (Fig. 2D). There was no signifi-
cant difference between the number of TH and NeuN positive dopamine neurons between
Nurr1 agonist and vehicle treatment conditions on the contralateral side (vehicle = 7441 ± 491.6;
SA00025 = 7916 ± 408.1, T1,16 = 0.27, p = n.s), following injection with the TLR3 Stimulant
polyI:C. The intensity of TH staining within individual dopaminergic cell bodies of Nurr1
treated rats was significantly higher compared to vehicle conditions on the ipsilateral side (ve-
hicle = 36 ± 3.12; SA00025 = 47.6 ± 4.01, T1,16 = 2.18, p<0.05) and the contralateral side (vehi-
cle = 38.15 ± 2.11; SA00025 = 47.1 ± 3.21, T1,16 = 2.33, p<0.05). Dopamine neuron fibers
in the rostral striatum were also significantly spared with administration of the compound
(T1,16 = 1.86, p<0.05), compared to vehicle treatment (Fig. 2E).
SA00025 displayed anti-inflammatory activity in the 6-OHDA lesion
model primed with the TLR3 dsRNA inflammatory stimulant (poly(I:C))
At the end of Nurr1 agonist administration to rats that received an intra-nigral poly(I:C) injec-
tion followed by an intra-striatal 6-OHDA injection, we found that there was a significant mor-
phological change of IBA-1 positive microglia in the SNpc. SA00025 treatment caused
significantly more microglia residing in a resting state (ramified morphology) and a significant
decrease in reactive microglia (bushy morphology) (F3,40 = 3.49, p<0.05) compared to vehicle
treatment (Fig. 3A), depicted in (Fig. 3B). There was no significant difference in the total
amount of microglia between vehicle and Nurr1 agonist treated groups (T1,16 = 0.98, p = n.s.).
SA00025 treatment caused a reduction in the immunofluorescence intensity of both IBA-1
positive microglia and GFAP positive astrocytes in the SNpc compared to vehicle treatment
(Fig. 3C). Optical density analysis indicated that SA00025 administration caused a significant
decrease of both IBA-1 (T1,16 = 3.09, p<0.05) and GFAP (T1,16 = 3.86, p<0.05) immunofluo-
rescence (Fig. 3D-E).
The protein levels of several key proinflammatory cytokines were then assessed in the SN of
rats treated with the compound or vehicle. A significant reduction in IL-6 was observed with
Nurr1 agonist treatment (T1,16 = 1.96, p<0.05), yet IL10, IL1a, MCP1, MIP1a, MIP2, MIP3a,
RANTES, Fractalkine, TNFa, ILb, IL-2, MDC and TGFb1 remained unchanged (Table 1).
Discussion
The transcription of Nurr1 has fundamental roles to maintain the midbrain dopamine neuro-
nal phenotype [1,2,23] and decrease the response to inflammatory insults [18] in vivo. In our
Nurr1 Agonist Treatment in a Parkinson's Disease Rat Model
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Fig 2. SA00025 caused neuroprotection in the 6-OHDA lesion model primed with dsRNA inflammatory stimulant (poly(I:C)). Rats received an initial
unilateral injection of poly(I:C) in the SN (Start—day 0) and a subsequent unilateral injection of 6-OHDA in the striatum (day 12) (A). Rats were also
administered daily with the Nurr1 agonist (30mg/kg/ day) or vehicle treatment throughout the paradigm (day 1–32) and were sacrificed at day 33 (A). 24 hrs
following the last gavage treatment levels of the compound were significantly elevated in brain homogenates and was absent in vehicle treated conditions
(B). Representative photomicrographs indicate the Nurr1 agonist caused a protective affect on TH +ve (brown) and NeuN +ve (grey) neurons within the SNpc
Nurr1 Agonist Treatment in a Parkinson's Disease Rat Model
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and TH +ve fibers in the striatum (C). Rats had a significant sparing of dopaminergic neurons in the SNpc after 32 days of treatment with the compound,
compared to vehicle treatment (D). Dopamine neuron fibers in the rostral striatum were also significantly spared with Nurr1 agonist treatment compared to
vehicle treatment (E). Significance is annotated as p<0.05*, unpaired T-tests. N = 6–8/ group. Graphs are expressed at mean ± SEM. Abbreviations: dorsal
lateral striatum (DL Stri) & medial striatum (M Stri). Scale bars = 200μm. TH and NeuN +ve neurons are indicated by black arrow heads and NeuN +ve
neurons are indicated by grey arrows.
doi:10.1371/journal.pone.0121072.g002
Fig 3. SA00025 induced anti-inflammatory activity in the 6-OHDA lesion model primed with dsRNA inflammatory stimulant (poly(I:C)). There was a
significant increase in the amount IBA-1 +ve microglia in the SNpc scored as rating 1 (ramified and resting) and a significant decrease in microglia scored at
rating 3 (bushy and reactive) with 32 days of Nurr1 agonist treatment, compared to vehicle (A). Representative photomicrographs show that Nurr1 agonist
treatment caused a reduction in IBA-1 +ve microglia that were bushy and reactive and an increase in IBA-1 +ve microglia that were ramified and resting in the
SNpc (B). Representative photomicrographs show that Nurr1 agonist treatment also caused a reduction in the immunofluorescent intensity of IBA-1 +ve
microglia (green) and GFAP +ve astrocytes (C). Optical density analysis indicated that Nurr1 agonist treatment caused a significant decrease in IBA-1 (D)
and GFAP (E) staining in the SNpc, compared to vehicle conditions. Significance is annotated as p<0.05*, 2- way ANOVA. N = 6–8/ group. Graphs are
expressed at mean ± SEM. Scale bars = 100μm.
doi:10.1371/journal.pone.0121072.g003
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model viral-like stimulation was induced using poly(I:C), causing an exacerbated response to
subsequent oxidative stress [20]. It has been proposed that inflammogens, such as viruses, may
play an etiological role in the development of PD and may exacerbate pathogenesis through the
TLR signaling pathways [19]. Inflammation exacerbates dopamine neuron degeneration in
vivo caused by a-synuclein overexpression [24], deficiencies in known PD risk genes [25,26]
and pesticide exposure [27,28]. Therefore we have explored the therapeutic potential of a novel
Nurr1 agonist, SA00025, compound to prevent the degeneration of dopamine neurons in an
animal model of PD, primed with TLR3 activator poly(I:C).
We first confirmed that a single and chronic dosing of SA00025 was able to achieve signifi-
cant brain levels with an extended half-life and it therefore has a favorable kinetic profile. Since
physiologically active Nurr1 initiates and maintains the transcription of TH, VMAT, DAT and
AADC [1,2], required for dopamine handling, synthesis and release, we then tested whether
the Nurr1 agonist could modulate the transcription of these genes. Following a 7-day daily dos-
ing treatment regime Nurr1, TH and VMAT were upregulated 1 hr after the last administra-
tion in the midbrain, confirming the action of the compound to induce Nurr1-dependant
dopaminergic target gene transcription in vivo. At 4hrs TH protein levels were increased yet
the transcription of TH was decreased. We suggest that the transcriptional repression of TH
was caused by the increase in TH protein levels, possibly acting as a compensatory response to
normalize TH protein levels to baseline. Nurr1, TH and VMAT were either downregulated or
normalized at 4 hrs after the final administration. This likely occurs because of a tight regulato-
ry system acting to compensate in response to the induced increase in protein levels. Nurr1
also controls the transcription of the GDNF receptor, c-Ret, and upregulation of this gene was
seen at 24 hrs, indicating a slower transcriptional regulation than dopaminergic target genes.
Nurr1 is an essential regulator for Ret expression in dopamine neurons [29,30] and increasing
levels of c-ret may therefore enhance neurotrophic signaling [16] and TH mRNA levels [31].
We evaluated whether SA00025 caused neuroprotection in an oxidative stress rodent model
of PD primed with polyI:C [20]. Using this model, we showed a protection of dopamine
Table 1. Cytokine and Chemokine protein levels in the SNpc following Nurr1 agonist treatment.
Cytokines & chemokines a Poly(I:C) & 6-OHDA Vehicle treatment Poly(I:C) & 6-OHDA Nurr1 agonist treatment
IL10 3.62 ± 0.84 2.17 ± 0.54
IL1a 1.40 ± 0.30 1.98 ± 0.19
IL6 144.59 ± 24.63 90.51 ± 21.94*#b
MCP1 22.97 ± 3.65 20.20 ± 1.75
MIP1a 2.79 ± 0.40 2.62 ± 0.35
MIP2 0.52 ± 0.06 0.66 ± 0.13
MIP3a 3.89 ± 0.56 4.18 ± 0.57
RANTES 8.77 ± 0.52 8.03 ± 0.48
TNFa 11.93 ± 1.46 18.14 ± 6.12
Fractalkine 65.78 ± 4.50 62.44 ± 5.18
IFNg 106.76 ± 16.81 95.36 ± 9.26
IL1b 30.51 ± 4.69 29.84 ± 1.35
IL2 10.97 ± 2.16 9.01 ± 1.24
MDC 0.11 ± 0.01 0.11 ± 0.01
TGFb1 137.47 ± 35.98 123.31 ± 10.46
a Cytokines and chemokine levels in the SN (pg/mg), analyzed by multiplex ELISA
b Data is represented as mean ± SEM and signiﬁcance is annotated as *p<0.05
doi:10.1371/journal.pone.0121072.t001
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neurons in the SNpc and data to support that dopaminergic fibers were also spared in the stria-
tum. The immunoreactivity of TH within dopamine cell bodies was also increased by SA00025
indicating that remaining dopamine neurons may also have a greater capacity for neurotrans-
mitter synthesis. We have previously found that the inflammatory response initiated by the
polyI:C injection induces a shift in microglial morphology that corresponds to a more reactive
state and an increase in the proinflammatory cytokines and chemokines: IL-1b, IL-6, TNFa,
MCP-1, RANTES and TGFb1 [20]. We have also previously shown that pro-inflammatory
triggers were associated with enhanced dopaminergic degeneration [20,21]. In this paradigm,
Nurr1 agonist treatment was associated with a decrease in reactive microglial morphology and
a decrease in the optical density of GFAP positive astrocytes. At the time of post mortem, cyto-
kine and chemokine analysis revealed that the Nurr1 agonist treatment could selectively reduce
IL-6 in the SNpc. It is also possible that Nurr1 agonist treatment may alter the expression of
other inflammation associated chemokines and cytokines at different time points post intracra-
nial injections of polyI:C and 6-OHDA. IL-6 is secreted by macrophages and T-cells upon
TLR3 stimulation [20,32,33,34,35], and is downstream of the Fas ligand pathway [36,37]. This
pathway and IL-6 is enhanced in both PD patients [37,38] and in mice exposed to MPTP and
6-OHDA [39,40]. IL-6 has also been shown to be significantly elevated in cases of traumatic
brain injury [41], Alzheimer’s disease [42] and Huntington’s disease [43]. This supports the
idea that the long-term action of the Nurr1 agonist to decrease IL-6 may be beneficial in PD
and other inflammatory related neurological disorders. The reduction of IL-6 by Nurr1 agonist
treatment may occur because it promotes the removal of NF-kB from the promoter regions of
proinflammatory cytokine genes [18]. Given this hypothesis it is also possible that the phos-
phorylation state of NF-kB may be altered and this warrants further investigation.
In addition to oxidative stress, genetic models of PD are also associated with inflammation.
Reactive microglia morphological changes and proinflammatory cytokine expression are ob-
served in the prodromal phases of the AAV-A53T a-synuclein induced neurodegeneration
model [44], and isolated microglia cells from the transgenic mutant LRRK2 (R1441G) mouse
model have a more reactive profile compared to wild-type cells [45]. Genetically obliterating
LRRK2 in vivo causes neuroprotection against a-synuclein overexpression by suppressing the
recruitment of chronically activated proinflammatory myeloid cells to the site of injury [46].
Therefore Nurr1 agonist treatment is also a candidate for the treatment of genetic forms of PD,
including the most prevalent LRRK2 mutation causing form, and may help mitigate immune
cell recruitment and decrease local inflammation.
Conclusions
Based on these findings we conclude that Nurr1 agonist treatment warrants further investiga-
tion as a PD therapy. There may be several benefits of increasing Nurr1 activity. Firstly, since
Nurr1 is downregulated in both normal aging [10] and in PD patients [11,12], Nurr1 agonist
treatment may help to improve dopamine synthesis, handling and release during aging and
after significant degeneration. Secondly, our data support an anti-inflammation role, which
may be advantageous in the initial stages of PD, since neuronal degeneration may be triggered
and exacerbated by inflammatory insults [19].
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